Manhattan Research Releases Latest Study Focused on How Nurses Use the Internet and Technology

Manhattan ResearchPharmaceutical and healthcare market research company Manhattan Research releases Taking the Pulse® Nurses v10.0, the latest iteration of its study focused on how nurses use digital resources, handheld devices, and other technologies in the professional setting. The market research and advisory service is based on in-depth interviews with over 1,000 U.S. nurses and physician assistants (PAs). Broad nurse market research can be segmented to provide insights for more than twenty specialist groups, including oncology, diabetes, and cardiology.

"With growing pressure to maximize prescription drug sales, marketers are increasingly looking to leverage highly influential touch points in the healthcare system beyond physicians, including nurses, payers, and pharmacists," said Monique Levy, Senior Director of Research at Manhattan Research. "Nurses represent a particularly strong opportunity for marketers - especially from a competitive standpoint - because their Internet and digital media adoption is highly advanced, but only a handful of brands have invested in the channel to date."

Key topics covered in the research include:

  • Technology and Internet Use for Professional Purposes: Technology and device ownership, websites visited during appointments, search engines, wikis, social networking websites, HCP online communities, newsletters, blogs, podcasts, attitudes toward Internet usage
  • Channel Mix: Sources used for professional information, including medical references, journals, and conferences
  • Email Use & Opportunity: Email usage and patient messaging/communication
  • Patient Interaction & Education: Source of patient education materials, websites recommended, influence on treatment decisions
  • Handheld Devices: Frequency, professional functions, clinical references, preferred points of access
  • Practice Technology: Electronic prescribing, EMR use and activities
  • Continuing Education: Current and future manner of completion (online, mobile, traditional), websites used
  • Practice Profile: Work setting, number of patients seen, number of prescriptions written
  • Digital Interaction with Pharma and Healthcare Companies: Top pharma properties, website features of interest, HCP service portals

About Taking the Pulse® Nurses
Taking the Pulse® Nurses was conducted in Q2 2010 among a nationally representative sample of 1,023 U.S. practicing nurses and physician assistants (PAs) via online survey methodology.

Healthcare and pharmaceutical marketers and other industry stakeholders use Taking the Pulse® Nurses to examine technology, media, channel, and promotional mix strategies as well as to benchmark their performance against industry competitors. In addition to analyzing overall market trends, clients can segment the study to derive statistically relevant insights across more than twenty specialist groups.

For additional product and subscription information, please visit http://www.manhattanresearch.com/ttpnurses.

About Manhattan Research
Manhattan Research, a Decision Resources, Inc. company, is a global pharmaceutical and healthcare market research and strategic advisory firm and conducts annual research studies covering eHealth trends among physicians and consumers, including Taking the Pulse®, Taking the Pulse® Nurses, Taking the Pulse® Europe, Taking the Pulse® Asia, Cybercitizen Health®, Cybercitizen Health® Europe, ePharma Consumer®, and ePharma Physician®. Broad consumer and physician research is complemented by targeted analysis for over 100 consumer therapeutic segments and physician specialist segments. For more information, please visit http://www.manhattanresearch.com.

About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.decisionresourcesinc.com.

Most Popular Now

BioMotiv and Bristol-Myers Squibb announce the lau…

BioMotiv, a mission-driven drug development accelerator associated with The Harrington Project for discovery and development, that advances breakthrough discoveries from ...

CEPI and GSK announce collaboration to strengthen …

CEPI, the Coalition for Epidemic Preparedness Innovations, and GSK announced a new collaboration aimed at helping the global effort to develop a vaccine for the 2019-nCoV...

Sandoz completes acquisition of Aspen's Japanese o…

Sandoz today announced that it has successfully completed the acquisition of the Japanese business of Aspen Global Incorporated (AGI), a wholly owned subsidiary of Aspen ...

Sanofi brain-penetrant BTK inhibitor meets primary…

The Sanofi Phase 2b study evaluating its investigational BTK (Bruton's tyrosine kinase) inhibitor (SAR442168), an oral, brain-penetrant, selective small molecule, achieve...

Roche reports very strong results in 2019

In 2019, Group sales rose 9% to CHF 61.5 billion and core EPS grew 13%, ahead of sales. The core operating profit increased 11%, reflecting the strong underlying business...

Merck donates one billionth praziquantel tablet

Merck, a leading science and technology company, today announced that it has already donated 1 billion tablets of praziquantel, the standard medication for the treatment ...

Bayer and Nuvisan create new research unit in Berl…

Bayer AG today announced that it entered into a definitive agreement to transfer a large part of its Berlin-based small molecule research unit to Nuvisan, an internationa...

Novartis announces MET inhibitor capmatinib (INC28…

Novartis announced that the US Food and Drug Administration (FDA) accepted and granted Priority Review to capmatinib’s (INC280) New Drug Application (NDA). Capmatinib is ...

WHO, China leaders discuss next steps in battle ag…

The Director-General of the World Health Organization (WHO), Dr Tedros Adhanom Ghebreyesus, met President Xi Jinping of the People's Republic of China in Beijing. They sh...

FDA approves first drug for treatment of peanut al…

Today the U.S. Food and Drug Administration approved Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp] to mitigate allergic reactions, including anaphylaxis, tha...

Can bilingualism protect the brain even with early…

A study by York University psychology researchers provides new evidence that bilingualism can delay symptoms of dementia. Alzheimer's disease is the most common form of d...

Poliovirus therapy shows potential as cancer vacci…

A modified form of poliovirus, pioneered at Duke Cancer Institute as a therapy for glioblastoma brain tumors, appears in laboratory studies to also have applicability for...